Remedy Pharmaceuticals
Company profile
Remedy Pharmaceuticals
remedypharmaceuticals.comHeadquarters: United States
11-50 employeesProduct Vendor
Primary focus
Developing treatments for acute central nervous system (CNS) injuries and diseases, with an emphasis on therapies for severe ischemic stroke.
Why it’s included
The company develops CIRARA, an intravenous small-molecule SUR1-TRPM4 channel inhibitor for acute CNS injury, and has conducted its own clinical trials in brain contusion and holds patents for treating CNS edema, directly matching the topic's requirements for a central TBI drug sponsor.
Relevant capabilities
- Imaging-based lesion volume assessment using CT perfusion and MRI
- Development of intravenous small-molecule formulation
- Design and conduct of randomized, double-blind, placebo-controlled clinical trials
- Regulatory engagement and program strategy with FDA
- Clinical data analysis, subgroup and post hoc statistical evaluation
Commercial sectorEdema, Barrier, and Bleeding Therapeutics
Technology classesSUR1-TRPM4 channel inhibition for cerebral edema
Relevant commercial products
- Intravenous glyburide formulation (investigational therapeutic for large hemispheric infarction)
- CIRARA
Relevant patents
3 families, 5 publications- Methods of treating injuries or conditions related to CNS edema US-11951085-B2
- Methods of medical treatment with SUR1-TRPM4 channel inhibitors US-11304963-B2
- Methods of treating ischemic stroke at risk for cerebral or cerebellar edema US-12251388-B1